Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib PK in Healthy Chinese Subjects
NCT02097433Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Time to Reach Maximum Observed Plasma Concentration at 264 hours, Maximum Observed Plasma Concentration at 264 hours and 4 more. Started Jul 2014; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02097433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097433.